Docoh
Loading...

AIKI AIkido Pharma

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Company profile

Ticker
AIKI
Exchange
CEO
Anthony Hayes
Employees
Incorporated
Location
Fiscal year end
Former names
BIOSPHERICS INC, SPHERIX INC
SEC CIK
IRS number
520849320

AIKI stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

10 May 21
28 Jul 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 7.98M 7.98M 7.98M 7.98M 7.98M 7.98M
Cash burn (monthly) (positive/no burn) (positive/no burn) 772.67K 538.75K 351K 302.17K
Cash used (since last report) n/a n/a 3.02M 2.11M 1.37M 1.18M
Cash remaining n/a n/a 4.96M 5.87M 6.61M 6.8M
Runway (months of cash) n/a n/a 6.4 10.9 18.8 22.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
3 May 21 Hayes Anthony Common Stock Buy Aquire P No No 0.99 10,000 9.9K 78,430
29 Apr 21 Hayes Anthony Common Stock Buy Aquire P No No 0.99 10,000 9.9K 68,430
22 Apr 21 Hayes Anthony Common Stock Buy Aquire P No No 0.93 10,000 9.3K 58,430
26 May 20 AIkido Pharma Common Stock Sell Dispose S No No 1.25 400,000 500K 1,130,674

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Management Discussion
  • The Company experienced very little or no revenue in the last two years and we don’t expect any revenue until a biotechnology product is fully developed which may not occur for many years.
  • For the year ended December 31, 2020 and 2019, we incurred a loss from operations of $6.5 million and $5.7 million, respectively. The increase in loss was primarily attributed to $1.0 million increase in other research and development expense, and $0.9 million increase in general and administrative expenses, partially offset by $1.0 million decrease in research and development expense incurred in connection with the license acquired.
  • For the year ended December 31, 2020 and 2019, other (expense) income was approximately $(5.8) million and $1.5 million, respectively. The increase in other expense was primarily attributed to a $8.2 million decrease in change in fair value of investment in Hoth, due to the decrease in Hoth’s common stock price for the year ended December 31, 2020, and partially offset by $1.0 million increase in gains on marketable securities.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Bad
New words: accelerated, annum, anticancer, antigen, arrangement, ASC, award, Bander, bifurcation, brain, chapter, check, claim, committee, compensation, confusion, consideration, Convergent, Cornell, decision, delivered, depression, dysfunction, electronically, embedded, emerging, Employer, enterprise, equal, filer, Florida, forward, host, improve, instrument, Interactive, invented, IP, irrevocable, jurisdiction, mark, Master, mature, maturity, Medicine, membrane, MLA, Moving, nausea, Neil, neural, neuroinflammation, NNPT, noncurrent, nonrefundable, Nuta, original, overallotment, Page, pain, par, Parma, peptide, posted, preservation, priority, Professor, promissory, provisional, PRRT, psilocybin, PSMA, qualitative, quantitative, radionuclide, receptor, representative, revised, running, separate, separately, shell, Silo, simplify, Simplifying, SMS, SMSI, SPAII, sublicensable, Subsidiary, Title, type, underwriter, underwriting, underwritten, unpaid, Unregistered, unvested, Urologic, vested, Wainwright, Washington, Weill
Removed: ability, acceptable, accounted, accretion, acquiring, add, administration, agent, applicable, approval, approved, assessment, atopic, attributable, August, average, Basic, begin, beneficial, bid, BioPharma, biopharmaceutical, blockchain, calculation, calendar, carrying, CBM, Certificate, clinical, clinically, close, closing, combat, commence, communication, compliance, comply, comprise, computed, conduct, conform, consecutive, consist, consuming, continued, continuing, credit, DatChat, dated, declared, deemed, deficiency, designate, Designation, develop, digital, dilutive, direct, distribute, distribution, dividing, documented, eczema, efficacy, enacted, encrypted, enter, entity, eventually, exceed, execute, expansion, expensive, experience, expire, extent, extinguishment, failed, FDA, feature, federal, fee, final, focusing, foregoing, fourth, Framework, funding, governmental, hierarchy, holder, iii, immaterial, implemented, increasing, incremental, IND, informing, infrastructure, inhibit, internet, issuable, June, letter, life, limit, listing, longer, made, maintenance, manufacturing, Marketplace, meant, medical, meet, minimum, model, modify, monetization, monetizing, monitoring, mouse, movement, notice, offered, office, ownership, party, percentage, performed, personal, pharmaceutical, placement, plan, pricing, primary, privacy, privately, proposed, prosecuted, prosecution, publicly, record, reduce, regain, regulatory, relevant, rely, remove, replication, require, requirement, review, reviewed, safety, schedule, scope, Secretary, secure, security, seek, shareholder, spread, stage, strategic, successful, successfully, suffering, sufficient, system, terminated, termination, test, testing, timeline, trademark, transgenic, transitioning, treasury, treat, trial, unmet, update, volatility, VStock, weighted